Glaucoma News

Patient-reported symptoms of glaucoma, including blurry vision, sensitivity to light and little peripheral vision, explain the variance in visual field damage, according to a cross-sectional study in Ophthalmology.

A newly developed handheld chromatic pupillometer has shown accuracy in revealing pupillometric dysfunctions in patients with varying severity of glaucoma, according to data published in British Journal of Ophthalmology.

Topical glaucoma medication may alter the structure and function of patients’ meibomian glands, particularly if preservative is present in the drop, according to data published in Optometry and Vision Science.

Transitioning from SITA Standard to SITA Faster may improve visual field performance in moderate to advanced glaucoma but may conceal disease progression, according to a retrospective, longitudinal study.

BOSTON – Vivid Vision software is indicated for treating convergence insufficiency, stereo depth perception, amblyopia and strabismus either in the clinic or at home, according to a presentation here at the American Academy of Optometry meeting.

BOSTON — The new FMAT1 measures tonometry, ophthalmodynamometry, tonography and ocular pulse amplitude, helping clinicians better manage glaucoma, J. James Thimons, OD, said at the American Academy of Optometry annual meeting.

BOSTON – The re:Vive from Heru is a wearable, modifiable, gameable, portable visual field system that can be used in a brightly lit room, Mitch Ibach, OD, said here at the American Academy of Optometry meeting.

BOSTON – The iStent inject and iStent inject W are trabecular meshwork bypass technologies performed to reduce patients’ risk of glaucoma progression and decrease medication burden, Mitch Ibach, OD, said here at the American Academy of Optometry meeting.

NEW ORLEANS — After 5 years of follow-up, eyes that received the Hydrus microstent for mild to moderate glaucoma required fewer medications and surgeries compared with eyes that underwent cataract surgery alone, according to a study.

The FDA has issued an investigational device exemption for a clinical study to evaluate the safety and effectiveness of a higher-volume Omni device for canal viscodilation in adults with primary open-angle glaucoma.